With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug
Xconomy
SEPTEMBER 30, 2020
The study was small and was not designed to show statistical significance. On Wednesday, New York-based Ovid (NASDAQ: OVID ) reported Phase 2 results showing that the molecule, soticlestat, reduced the frequency of epileptic seizures in CDKL5 deficiency disorder (CDD) and chromosome 15q duplication (Dup15q) syndrome.
Let's personalize your content